Joseph Boscia, MD
Pulmonary Disease · Spartanburg, SCNPI 1669437257
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $589,580 of the $701,106 with a category attached, or 84.1%. GSK accounts for 88.1% of it on its own, with 51 other manufacturers making up the rest. Reporting peaked in 2023 at $173,302 and has fallen 56.2% since, to $75,953 in 2025. Among pulmonary disease clinicians in SC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,557 payments — averaging $450.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$618K
- Mallinckrodt Hospital Products Inc.$63K
- AstraZeneca$4K
- Boehringer Ingelheim$2K
- Actelion Pharmaceuticals US, Inc.$2K
- Viiv Healthcare Company$2K
- plus $11K from 46 others
Across 681 payments — averaging $11,140 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$2.6M
- AstraZeneca$1.2M
- Modernatx, Inc.$898K
- Boehringer Ingelheim$672K
- Pfizer$476K
- Seqirus USA Inc$332K
- plus $1.5M from 14 others
What the payments were for
- Consulting fees$9,1001%
- Speaking & faculty fees$589,58084%
- Travel & lodging$71,59110%
- Food & beverage$30,6224%
- Education$1550%
- Gifts$580%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TRELEGY ELLIPTA$182,127
- AREXVY$150,245
- NUCALA$73,509
- ACTHAR$62,133
- ANORO$31,138
- FASENRA$1,574
- ANORO ELLIPTA$1,200
- BREZTRI$827
- TEZSPIRE$766
- AIRSUPRA$736
- FARXIGA$370
- BEVESPI AEROSPHERE$370
- UPTRAVI$367
- OPSUMIT$367
- DUPIXENT$345
- WINREVAIR$245
- TAGRISSO$163
- OFEV$125
- SYMBICORT$113
- Monarch Platform$113
How this compares
$701,106 in reported general payments places this provider in the 95th percentile of 192 pulmonary disease providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ActharCorticotropin | 21 | $977,000 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 1,037 | $838,268 |
| OfevNintedanib Esylate | 36 | $472,015 |
| Dupixent PenDupilumab | 75 | $372,178 |
| NucalaMepolizumab | 47 | $182,025 |
| EsbrietPirfenidone | 18 | $181,272 |
| GlassiaAlpha-1-Proteinase Inhibitor | 14 | $177,097 |
| XolairOmalizumab | 44 | $166,804 |
| Ambrisentan | 39 | $145,271 |
| ZemairaAlpha-1-Proteinase Inhibitor | 17 | $124,495 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 136 | $110,998 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 223 | $109,958 |
| Breo ElliptaFluticasone/Vilanterol | 215 | $109,415 |
| Spiriva RespimatTiotropium Bromide | 128 | $107,582 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 75 | $55,893 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Nucala, Anoro Ellipta, Breo Ellipta, Incruse Ellipta | $617,510 | $1,262,8471,590 claims |
| Mallinckrodt Hospital Products Inc.Acthar | $63,163 | $977,00021 claims |
| Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat, Combivent Respimat | $1,935 | $649,108266 claims |
| Genentech USA, Inc.Esbriet | $100 | $181,27218 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Glassia | $563 | $177,09714 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $4,015 | $149,443243 claims |
| MerckDulera | $468 | $7,48412 claims |
| Teva Pharmaceuticals USA, Inc.Qvar Redihaler, Albuterol Sulfate | $90 | $4,85230 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 192 pulmonary disease providers in South Carolina.
Other pulmonary disease in Spartanburg
- Farhan SiddiquiSpartanburg$24K
- David ErbSpartanburg$12K
- Charles FogartySpartanburg$10K
- Abhijit RavalAnderson$2M
- Richard BoganColumbia$1.1M
- Patrick FlumeCharleston$418K
- Sean CallahanGreenville$321K
- Laura HerpelColumbia$254K
- Gerard SilvestriCharleston$254K
- Arun AdlakhaRock Hill$184K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.